<p>令一些股东感到恼火的是，<strong>Health Catalyst, Inc.</strong>（纳斯达克代码：HCAT）的股价在过去一个月下跌了 27%，这延续了该公司的糟糕表现。最近的下跌使得过去一年股东的损失达到了 51%。</p>
<p>由于股价大幅下跌，Health Catalyst 的市销率（&#34;P/S&#34;）为 1 倍，这使得与美国医疗服务行业相比，它看起来像是一个买入机会，因为该行业大约一半的公司市销率超过 2.2 倍，甚至超过 7 倍的市销率也相当普遍。不过，仅仅根据市销率来判断并不明智，因为可能有原因导致其受到限制。</p>
<p>查看我们对 Health Catalyst 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893"/></p>
<p>纳斯达克 GS:HCAT 市销率与行业比较 2025 年 3 月 8 日</p>
<h3>Health Catalyst 的市销率对股东意味着什么？</h3>
<p>最近一段时间，Health Catalyst 的表现并不理想，因为其收入增长速度低于大多数其他公司。也许市场预计当前的收入增长乏力趋势将持续，这使得市销率受到压制。如果你仍然看好这家公司，你会希望收入不会进一步恶化，并希望在它不受欢迎时能够买入一些股票。</p>
<p>如果你想了解分析师对未来的预测，可以查看我们关于 Health Catalyst 的 <strong>免费</strong> 报告。</p>
<h2>Health Catalyst 是否有收入增长的预测？</h2>
<p>有一个内在的假设，即公司应该低于行业表现，才能使像 Health Catalyst 这样的市销率被认为是合理的。</p>
<p>如果我们回顾过去一年的收入增长，公司实现了 3.6% 的可观增长。最近三年期间，收入总体增长了 27%，在一定程度上得益于其短期表现。因此，股东们可能对中期的收入增长率感到满意。</p>
<p>展望未来，分析师预计在接下来的三年中，收入将以每年 9.8% 的速度增长。这与更广泛行业的 11% 年增长预测相似。</p>
<p>考虑到这一点，我们发现 Health Catalyst 的市销率落后于其行业同行，这一点颇具吸引力。显然，一些股东对预测表示怀疑，并接受了较低的出售价格。</p>
<h2>我们可以从 Health Catalyst 的市销率中学到什么？</h2>
<p>Health Catalyst 最近疲软的股价使其市销率低于其他医疗服务公司。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>我们对 Health Catalyst 的分析显示，尽管分析师预测的收入增长与更广泛的行业相匹配，但其市销率仍然较低。当我们看到这样的中等收入增长时，我们假设潜在风险是施加压力于市销率的原因。显然，有些人确实在预期收入的不稳定，因为这些条件通常应该为股价提供更多支持。</p>
<p>在投资之前，还有其他重要的风险因素需要考虑，我们发现 <strong>Health Catalyst 有 2 个警告信号</strong>，你应该注意。</p>
<p>如果你对盈利能力强的公司感兴趣，那么你会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司以低市盈率交易（但已证明它们能够增长盈利）。</p>
<p>如果你打算交易 Health Catalyst，可以在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

HCAT

<p>Health Catalyst, Inc.（纳斯达克代码：HCAT）股票在过去一个月下跌了 27%，导致过去一年损失达 51%。尽管其市销率（P/S）仅为 1 倍，显示出潜在价值，但收入增长却低于行业同行。分析师预测未来三年年收入将增长 9.8%，与行业平均水平相似。然而，投资者情绪依然谨慎，这体现在低市销率上，表明对收入稳定性的担忧。潜在投资者在做出决策前应考虑现有风险</p>

<p>To the annoyance of some shareholders, <strong>Health Catalyst, Inc.</strong> (NASDAQ:HCAT) shares are down a considerable 27% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 51% loss during that time.</p>
<div class="lb-trans"><p>令一些股东感到恼火的是，<strong>Health Catalyst, Inc.</strong>（纳斯达克代码：HCAT）的股价在过去一个月下跌了 27%，这延续了该公司的糟糕表现。最近的下跌使得过去一年股东的损失达到了 51%。</p>
</div><p>Since its price has dipped substantially, Health Catalyst's price-to-sales (or &#34;P/S&#34;) ratio of 1x might make it look like a buy right now compared to the Healthcare Services industry in the United States, where around half of the companies have P/S ratios above 2.2x and even P/S above 7x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's limited.</p>
<div class="lb-trans"><p>由于股价大幅下跌，Health Catalyst 的市销率（&#34;P/S&#34;）为 1 倍，这使得与美国医疗服务行业相比，它看起来像是一个买入机会，因为该行业大约一半的公司市销率超过 2.2 倍，甚至超过 7 倍的市销率也相当普遍。不过，仅仅根据市销率来判断并不明智，因为可能有原因导致其受到限制。</p>
</div><p>View our latest analysis for Health Catalyst</p>
<div class="lb-trans"><p>查看我们对 Health Catalyst 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893" alt="" original-src="https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893"/></p>
<p>NasdaqGS:HCAT Price to Sales Ratio vs Industry March 8th 2025</p>
<div class="lb-trans"><p>纳斯达克 GS:HCAT 市销率与行业比较 2025 年 3 月 8 日</p>
</div><h3>What Does Health Catalyst's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>Health Catalyst 的市销率对股东意味着什么？</h3>
</div><p>Recent times haven't been great for Health Catalyst as its revenue has been rising slower than most other companies. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>最近一段时间，Health Catalyst 的表现并不理想，因为其收入增长速度低于大多数其他公司。也许市场预计当前的收入增长乏力趋势将持续，这使得市销率受到压制。如果你仍然看好这家公司，你会希望收入不会进一步恶化，并希望在它不受欢迎时能够买入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Health Catalyst.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，可以查看我们关于 Health Catalyst 的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Health Catalyst?</h2>
<div class="lb-trans"><h2>Health Catalyst 是否有收入增长的预测？</h2>
</div><p>There's an inherent assumption that a company should underperform the industry for P/S ratios like Health Catalyst's to be considered reasonable.</p>
<div class="lb-trans"><p>有一个内在的假设，即公司应该低于行业表现，才能使像 Health Catalyst 这样的市销率被认为是合理的。</p>
</div><p>If we review the last year of revenue growth, the company posted a worthy increase of 3.6%. The latest three year period has also seen a 27% overall rise in revenue, aided somewhat by its short-term performance. Accordingly, shareholders would have probably been satisfied with the medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>如果我们回顾过去一年的收入增长，公司实现了 3.6% 的可观增长。最近三年期间，收入总体增长了 27%，在一定程度上得益于其短期表现。因此，股东们可能对中期的收入增长率感到满意。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 9.8% per annum during the coming three years according to the analysts following the company. That's shaping up to be similar to the 11% per annum growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未来，分析师预计在接下来的三年中，收入将以每年 9.8% 的速度增长。这与更广泛行业的 11% 年增长预测相似。</p>
</div><p>With this in consideration, we find it intriguing that Health Catalyst's P/S is lagging behind its industry peers. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.</p>
<div class="lb-trans"><p>考虑到这一点，我们发现 Health Catalyst 的市销率落后于其行业同行，这一点颇具吸引力。显然，一些股东对预测表示怀疑，并接受了较低的出售价格。</p>
</div><h2>What We Can Learn From Health Catalyst's P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Health Catalyst 的市销率中学到什么？</h2>
</div><p>Health Catalyst's recently weak share price has pulled its P/S back below other Healthcare Services companies. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>Health Catalyst 最近疲软的股价使其市销率低于其他医疗服务公司。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>Our examination of Health Catalyst's revealed that its P/S remains low despite analyst forecasts of revenue growth matching the wider industry. When we see middle-of-the-road revenue growth like this, we assume it must be the potential risks that are what is placing pressure on the P/S ratio. It appears some are indeed anticipating revenue instability, because these conditions should normally provide more support to the share price.</p>
<div class="lb-trans"><p>我们对 Health Catalyst 的分析显示，尽管分析师预测的收入增长与更广泛的行业相匹配，但其市销率仍然较低。当我们看到这样的中等收入增长时，我们假设潜在风险是施加压力于市销率的原因。显然，有些人确实在预期收入的不稳定，因为这些条件通常应该为股价提供更多支持。</p>
</div><p>There are also other vital risk factors to consider before investing and we've discovered <strong>2 warning signs for Health Catalyst</strong> that you should be aware of.</p>
<div class="lb-trans"><p>在投资之前，还有其他重要的风险因素需要考虑，我们发现 <strong>Health Catalyst 有 2 个警告信号</strong>，你应该注意。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你对盈利能力强的公司感兴趣，那么你会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司以低市盈率交易（但已证明它们能够增长盈利）。</p>
</div><p>If you're looking to trade Health Catalyst, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你打算交易 Health Catalyst，可以在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

在投资 Health Catalyst, Inc. (NASDAQ:HCAT) 之前要谨慎，尽管它的价格已经下降了 27%